Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (451-460 of 584) with videos related to

Pageof 59
Sort By:
Annals of Hematology|March 19, 2021
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
American Journal of Hematology|August 25, 2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeTalha Badar, Hagop M Kantarjian, Graciela M Nogueras-Gonzalez, et al.
British Journal of Haematology|June 16, 2017
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemiaNicholas J Short, Hagop Kantarjian, Elias Jabbour, et al.
The Journal of Arthroplasty|December 28, 2013
Prevention of late PJIAntonia Chen, Fares Haddad, Paul Lachiewicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDSMichael R Savona, Daniel A Pollyea, Wendy Stock, et al.
Blood Advances|April 8, 2026
Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-FirstMark J Levis, Harry P Erba, Pau Montesinos, et al.
Leukemia|February 4, 2014
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemiaF Ravandi, C Arana Yi, J E Cortes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2011
Influenza-like illness in a community surrounding a school-based outbreak of 2009 pandemic influenza A (H1N1) virus-Chicago, Illinois, 2009Kristen B Janusz, Jennifer E Cortes, Fadila Serdarevic, et al.
International Journal of Hematology|March 5, 2019
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Susan O'Brien, et al.
Acta Haematologica|August 3, 2018
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid LeukemiaIman Abou Dalle, Jorge E Cortes, Pramod Pinnamaneni, et al.
Pageof 59

Showing results (451-460 of 584) with videos related to

Sort By:
Pageof 59
Annals of Hematology|March 19, 2021
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
American Journal of Hematology|August 25, 2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeTalha Badar, Hagop M Kantarjian, Graciela M Nogueras-Gonzalez, et al.
British Journal of Haematology|June 16, 2017
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemiaNicholas J Short, Hagop Kantarjian, Elias Jabbour, et al.
The Journal of Arthroplasty|December 28, 2013
Prevention of late PJIAntonia Chen, Fares Haddad, Paul Lachiewicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDSMichael R Savona, Daniel A Pollyea, Wendy Stock, et al.
Blood Advances|April 8, 2026
Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-FirstMark J Levis, Harry P Erba, Pau Montesinos, et al.
Leukemia|February 4, 2014
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemiaF Ravandi, C Arana Yi, J E Cortes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2011
Influenza-like illness in a community surrounding a school-based outbreak of 2009 pandemic influenza A (H1N1) virus-Chicago, Illinois, 2009Kristen B Janusz, Jennifer E Cortes, Fadila Serdarevic, et al.
International Journal of Hematology|March 5, 2019
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Susan O'Brien, et al.
Acta Haematologica|August 3, 2018
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid LeukemiaIman Abou Dalle, Jorge E Cortes, Pramod Pinnamaneni, et al.
Pageof 59